natgillin/translations-raw huggingface dataset:
Co-administration with potent cytochrome P 450 (CYP) 3A4 inhibitors, such as ketoconazole, itraconazole, voriconazole, posaconazole, telithromycin, clarithromycin, nefazodone and ritonavir (see section 4.5)
Istodobna primjena s potentnim inhibitorima CYP3A4 citokroma P450, poput ketokonazola, itrakonazola, vorikonazola, posakonazola, telitromicina, klaritromicina, nefazodona i ritonavira (vidjeti dio 4.5)
Co-administration with potent P-gp or BCRP inhibitors may also alter the exposure and distribution of pazopanib, including distribution into the central nervous systems (CNS).
Istovremena primjena s potentnim inhibitorima P- gp ili BCRP-a također može promijeniti izloženost i distribuciju pazopaniba, uključujući i distribuciju u središnji živčani sustav (SŽS).
Co-administration with PREZISTA co-administered with cobicistat is not recommended (see section 4.4).
Ne preporučuje se istodobna primjena s lijekom PREZISTA istodobno primijenjenog s kobicistatom (vidjeti dio 4.4).
Co-administration with products containing St. John’s wort (Hypericum perforatum) (see section 4.5).
Istovremena primjena s lijekovima koji sadrže gospinu travu (Hypericum perforatum) (vidjeti dio 4.5).
Co-administration with propranolol can cause altered automaticity (excessive bradycardia, sinus arrest), sino-atrial and atrio-ventricular conduction disorders, and increased risk of ventricular arrhythmias (torsades de pointes) along with heart failure.
Istovremena primjena s propranololom može uzrokovati promjenu automatizma (prekomjernu bradikardiju, sinusni zastoj), poremećaje sinoatrijalne i atrioventrikularne provodljivosti te povećani rizik od ventrikularnih aritmija (torsades de pointes) kao i zatajenje srca.
Co-administration with REYATAZ/ritonavir may result in increased concentrations of salmeterol and an increase in salmeterol- associated adverse events.
Istovremena primjena s lijekom REYATAZ/ritonavirom može rezultirati povišenim koncentracijama salmeterola i pojačanim nuspojavama povezanima sa salmeterolom.
Co-administration with REYATAZ/ritonavir may result in increased concentrations of the PDE5 inhibitor and an increase in PDE5- inhibitor-associated adverse events.
Istovremena primjena s lijekom REYATAZ/ritonavirom može rezultirati povišenim koncentracijama inhibitora PDE5 i pojačanim nuspojavama povezanima s inhibitorom PDE5.
Co-administration with Stribild is not recommended.
Ne preporučuje se istovremena primjena sa Stribildom.
Co-administration with Stribild may lead to decreased elvitegravir and/or cobicistat exposures and loss of therapeutic effect and development of resistance.
Istovremena primjena sa Stribildom može dovesti do smanjene izloženosti elvitegraviru i/ili kobicistatu te do gubitka terapijskih učinaka i razvoja rezistencije.
Co-administration with Stribild may lead to increased tenofovir exposure.
Istovremena primjena sa Stribildom može povećati izloženost tenofoviru.
Co-administration with Stribild may result in increased plasma concentrations of salmeterol, which is associated with the potential for serious and/or life-threatening reactions.
Istovremena primjena Stribilda može za posljedicu imati povećane koncentracije salmeterola u plazmi, koji je povezan s potencijalno teškimi/ili smrtonosnim reakcijama.
Co-administration with Stribild may result in increased plasma concentrations of these drugs, which is associated with the potential for serious and/or life- threatening reactions.
Istovremenom primjena Stribilda može za posljedicu imati povećane koncentracije tih lijekova u plazmi, koji je povezano s potencijalno ozbiljnim i/ili smrtonosnim reakcijama.
Co-administration with Stribild may result in increased plasma concentrations of this drug.
Istovremena primjena Stribilda može za posljedicu imati povećane koncentracije ovog lijeka u plazmi.
Co-administration with strong CYP3A4 inhibitors is not recommended and caution is warranted, these interactions are described in the interaction table below (e.g. indinavir, systemic azoles like ketoconazole and clotrimazole).
Istodobna primjena sa snažnim CYP3A4 inhibitorima se ne preporučuje i savjetuje se oprez, ove interakcije opisane su u tablici interakcija ispod (npr. indinavir, sistemski azoli poput ketokonazola i klotrimazola).
Co-administration with strong CYP3A4/5 inducers such as rifampicin, rifabutin, carbamazepine, long- acting barbiturates (e.g. phenobarbital), phenytoin and St. John‟s wort or with moderate CYP3A4/5 inducers such as efavirenz, nafcillin and etravirine (see section 4.5).
Istodobna primjena sa snaţnim induktorima CYP3A4/5 poput rifampicina, rifabutina, karbamazepina, barbiturata s dugotrajnim djelovanjem (npr. fenobarbital), fenitoina i gospine trave ili s umjerenim induktorima CYP3A4/5 poput efavirenza, nafcilina i etravirina (vidjeti dio 4.5).
Co-administration with strong CYP3A4/5 inducers such as rifampicin, rifabutin, carbamazepine, long- acting barbiturates (e.g. phenobarbital), phenytoin and St. John‟s wort or with moderate CYP3A4/5 inducers such as efavirenz, nafcillin and etravirine (see section 4.5).
Istodobna primjena sa snaţnim induktorima CYP3A4/5 poput rifampicina, rifabutina, karbamazepina, barbituratima s dugotrajnim djelovanjem (npr. fenobarbital), fenitoina i gospine trave ili umjerenim induktorima CYP3A4/5 poput efavirenza, nafcilina i etravirina (vidjeti dio 4.5).
Co-administration with the following medicinal products due to the potential for serious and/or life- threatening adverse reactions (see section 4.5):
Istodobna primjena sa sljedećim lijekovima zbog mogućih ozbiljnih i/ili po život opasnih nuspojava (vidjeti dio 4.5):
Co-administration with the following medicinal products due to the potential for serious and/or life- threatening events or loss of therapeutic effect (see sections 4.4 and 4.5):
Istovremena primjena sa sljedećim lijekovima zbog mogućnosti ozbiljnih i/ili po život opasnih događaja ili gubitka terapijskog učinka (vidjeti dijelove 4.4 i 4.5):
Co-administration with the following medicinal products due to the potential for serious and/or life-threatening events or loss of virologic response and possible resistance to Stribild (see section 4.5):
Istovremena primjena sljedećih lijekova zbog mogućnosti teških i/ili smrtonosnih događaja ili gubitka virološkog odgovora i moguće rezistencije na Stribild (vidjeti dio 4.5):
Co-administration with the following medicinal products due to the potential for serious or life-threatening adverse reactions or loss of virologic response and possible resistance to Genvoya (see section 4.5):
Istodobna primjena sljedećih lijekova zbog mogućnosti teških ili životno opasnih nuspojava ili gubitka virološkog odgovora i moguće rezistencije na lijek Genvoya (vidjeti dio 4.5):
Co-administration with the following medicinal products that are strong inducers of the CYP3A4 isoform of cytochrome P450 due to the potential for loss of therapeutic effect (see section 4.5): carbamazepine, phenobarbital, phenytoin (antiepileptics)
Istodobna primjena sa sljedećim lijekovima, koji su snažni induktori izooblika CYP3A4 citokroma P450, zbog mogućeg gubitka terapijskog učinka (vidjeti dio 4.5):
Co-administration with transport substrates/inhibitors
Istodobna primjena sa supstratima/inhibitorima prijenosnika
Co-administration with Tybost is not recommended.
Ne preporučuje se istovremena primjena lijeka Tybost.
Co-administration with warfarin (a CYP2C9 substrate)
Istodobna primjena s varfarinom (supstrat CYP2C9)
Co-administration with warfarin (a CYP2C9 substrate)
Istodobna primjena s varfarinom (supstratom CYP2C9)
Co-administration with ZEPATIER is
Istodobna primjena s lijekom ZEPATIER je
Co-existing ophthalmic disease likely to require slit-lamp examination within the next 30 days.
Istovremeno prisutna očna bolest koja će vjerojatno zahtijevati pregled procjepnom svjetiljkom unutar sljedećih 30 dana.
Co-infected patients with advanced cirrhosis receiving combined anti-retroviral therapy (cART) may be at increased risk of hepatic decompensation and death.
Bolesnici s istodobnom infekcijom HCV-om i HIV-om s uznapredovalom cirozom koji primaju kombiniranu antiretrovirusnu terapiju (cART) mogu biti izloženi povećanom riziku od dekompenzacije jetre i smrti.
Co-infected patients with advanced cirrhosis receiving HAART may be at increased risk of hepatic decompensation and death.
Bolesnici s istodobnom infekcijom HCV-om i HIV-om i uznapredovalom cirozom jetre koji primaju vrlo djelotvornu antiretrovirusnu terapiju mogu imati povećan rizik od dekompenzacije jetre i smrti.
Co-infected patients with advanced liver disease receiving (HAART) may be at increased risk of worsening liver function.
Bolesnici s istodobnom infekcijom HIV-om i HCV-om koji imaju uznapredovalu bolest jetre i primaju HAART mogu imati povećan rizik od pogoršanja jetrene funkcije.
Co-infection with HBV (hepatitis B virus) or HCV (hepatitis C virus)
Istodobna infekcija virusom hepatitisa B (HBV) ili hepatitisa C (HCV)
Co-infection with hepatitis C or D: there are no data on the efficacy of entecavir in patients co-infected with hepatitis C or D virus.
Istodobna infekcija hepatitisom C ili D: nema podataka o djelotvornosti entekavira u bolesnika koji su istodobno inficirani virusom hepatitisa C ili D.
Co-infection with hepatitis C or D: There are no data on the efficacy of tenofovir in patients co-infected with hepatitis C or D virus.
Istovremena infekcija virusom hepatitisa C ili D: Ne postoje podaci o djelotvornosti tenofovira u pacijenata koji su istovremeno inficirani virusom hepatitisa C ili D.
Co-infection with HIV-1 and hepatitis B: Due to the risk of development of HIV resistance, tenofovir disoproxil fumarate should only be used as part of an appropriate antiretroviral combination regimen in HIV/HBV co-infected patients.
Istovremena infekcija HIV-om tipa 1 i HBV-om: Zbog rizika od razvoja rezistencije HIV-a, tenofovirdizoproksilfumarat mora se primjenjivati samo u sklopu odgovarajuće kombinacije antiretrovirusnog liječenja kod pacijenata istovremeno inficiranih HIV-om/HBV-om.
Co-medication of drugs increasing the upper gastro intestinal pH may lead to lower oral bioavailability.
Istodobno liječenje lijekovima koji povećavaju pH u gornjem dijelu gastrointestinalnog sustava mogu dovesti do smanjene bioraspoloživosti riocigvata nakon peroralne primjene.
Co-medication with selective serotonin re-uptake inhibitors (SSRIs) or selective serotonin norepinephrine re-uptake inhibitors (SNRIs)
Istovremena primjena sa selektivnim inhibitorima ponovne pohrane serotonina (SSRI-i) ili selektivnim inhibitorima ponovne pohrane serotonina i noradrenalina (SNRI-i)
Co-morbidity 0 or 1 (n=126)
popratne bolesti: 0 ili 1 (n=126)
Co-morbidity 2 or more (n=321)
popratne bolesti: 2 ili više (n=321)
Co-primary efficacy endpoints were overall survival and radiographic progression-free survival (rPFS).
Koprimarne mjere ishoda djelotvornosti bile su ukupno preživljenje i preživljenje bez radiografske progresije bolesti (rPFS prema engl. radiographic progression-free survival).
Co-primary endpoints: ARR & SAD.
Primarni ishodi: ARR i SAD.
Co-treatment with other drugs that are P-glycoprotein substrates/inhibitors (for example, ivermectin and other antiparasitic macrocyclic lactones, erythromycin, prednisolone and cyclosporine) could give rise to pharmacokinetic drug interactions.
Stoga istodobna primjena drugih veterinarsko medicinskih proizvoda koji su također supstrati ili inhibitori P-glikoproteina (npr. ivermektini i drugi antiparazitski makrociklični laktoni, eritromicin, prednizolon i ciklosporin) mogu potaknuti farmakokinetičke interakcije.
Co-treatment with other veterinary medicinal products that are P-glycoprotein substrates/inhibitors (for example, ivermectin and other antiparasitic macrocyclic lactones, erythromycin, prednisolone and cyclosporine) could give rise to pharmacokinetic interactions.
Istodobno tretiranje s drugim veterinarsko-medicinskim proizvodima koji su supstrat/inhibitor P-glikoproteina (na primjer, ivermektin i drugi antiparazitski makrociklički laktoni, eritromicin, prednisolon i ciklosporin) mogu dovesti do farmakokinetičke interakcije.
Co. Clare, Ireland
Clare, Irska
Co. Down, BT35 6JP
Co Down, BT35 6JP
Co. Galway,
Galway
Co. Galway, IRELAND
Galway IRSKA
Co. Galway, Ireland.
Galway Irska
CO2 absorbents should be replaced routinely regardless of the state of the colour indicator.
Apsorbere CO2 treba rutinski mijenjati bez obzira na boju indikatora.
coadministered with voriconazole 400 mg BID*
vorikonazolom u dozi od 400 mg BID
coadministered without dose adjustments.
Viramune i abakavir se mogu istodobno primjenjivati bez prilagodbe doze.
Coadministration of
Istodobna primjena vorikonazola
Coadministration of a single zaleplon 10 mg dose and venlafaxine (extended release) 75 mg or 150 mg daily did not produce any interaction on memory (immediate and delayed word recall) or psychomotor performance (digit symbol substitution test).
Istodobna primjena jednokratne doze zaleplona od 10 mg i venlafaksina (s produljenim oslobađanjem) od 75 mg ili 150 mg dnevno nije imala utjecaj na pamćenje (neposredno i odgođeno prisjećanje riječi) ili psihomotorne sposobnosti (test zamjene broja simbolom).
Coadministration of antipsychotic medicinal products with pramipexole should be avoided (see section 4.4), e.g. if antagonistic effects can be expected.
Treba izbjegavati istodobnu primjenu antipsihotičnih lijekova i pramipeksola (vidjeti dio 4.4), npr. ako se očekuju antagonistički učinci.
Coadministration of Corbilta with non-selective monoamine oxidase (MAO-A and MAO-B) inhibitors (e.g. phenelzine, tranylcypromine).
Istodobna primjena Corbilte s neselektivnim inhibitorima monoaminooksidaze (MAO-A i MAO-B) (npr. fenelzin, tranilcipromin).
Coadministration of corticosteroids (deflazacort, prednisone, or prednisolone) with ataluren did not affect the plasma concentrations of ataluren.
Istovremena primjena kortikosteroida (deflazakort, prednizon, ili prednizolon) s atalurenom nije utjecala na koncentracije atalurena u plazmi.
Coadministration of crizotinib with strong CYP3A inhibitors may increase crizotinib plasma concentrations.
Istodobna primjena krizotiniba sa snažnim inhibitorima CYP3A može povisiti koncentraciju krizotiniba u plazmi.
Coadministration of Daklinza with St. John’s wort or other strong inducers of CYP3A4 is contraindicated (see section 4.3).
Istodobna primjena lijeka Daklinza s gospinom travom ili drugim snažnim induktorima CYP3A4 je kontraindicirana (vidjeti dio 4.3).
Coadministration of dapagliflozin and metformin
Istodobna primjena dapagliflozina i metformina
Coadministration of Edarbi 40 and 80 mg with a calcium channel blocker (amlodipine) or a thiazide- type diuretic (chlortalidone) resulted in additional blood pressure reductions compared with the other antihypertensive alone.
Istovremena primjena Edarbija u dozi od 40 ili 80 mg s blokatorima kalcijevih kanala (amlodipinom) ili tiazidnom vrstom diuretika (klortalidonom) dovela je do dodatnog sniženja krvnog tlaka u usporedbi s drugim antihipertenzivom kad se primjenjivao sam.
Coadministration of Edarbi with diuretics, such as chlortalidone, resulted in a greater incidence of creatinine elevations, an observation consistent with that of other angiotensin II receptor antagonists and angiotensin converting enzyme inhibitors.
Istovremena primjena Edarbija s diureticima, kao što je klortalidon, rezultirala je većom incidencijom povišenja kreatinina i to je opažanje sukladno onome s drugim antagonistima receptora angiotenzina II i inhibitorima angiotenzin-konvertirajućeg enzima.
Coadministration of Eliquis and VKA therapy should be continued until the INR is ≥ 2.
Istodobnu primjenu lijeka Eliquis i antagonista vitamina K treba nastaviti dok INR ne bude ≥ 2,0.
Coadministration of Eliquis and VKA therapy should be continued until the INR is ≥ 2.
Istodobnu primjenu lijeka Eliquis i antagonista vitamina K treba nastaviti dok INR ne bude ≥ 2.
Coadministration of fentanyl with a serotoninergic medicinal product, such as a Selective Serotonin Re-uptake Inhibitor (SSRI) or a Serotonin Norepinephrine Re-uptake Inhibitor (SNRI) or a Monoamine Oxidase Inhibitor (MAOI), may increase the risk of serotonin syndrome, a potentially life-threatening condition.
Istodobna primjena fentanila sa serotoninergičkim lijekom, kao što je selektivni inhibitor ponovne pohrane serotonina (SSRI) ili selektivni inhibitor ponovne pohrane serotonina i noradrenalina (SNRI) ili inhibitor monoaminooksidaze (MAOI), može povećati rizik od pojave serotoninskog sindroma koji može biti opasan po život.
Coadministration of Ipreziv 40 and 80 mg with a calcium channel blocker (amlodipine) or a thiazide- type diuretic (chlortalidone) resulted in additional blood pressure reductions compared with the other antihypertensive alone.
Istovremena primjena Ipreziva u dozi od 40 ili 80 mg s blokatorima kalcijevih kanala (amlodipinom) ili tiazidnom vrstom diuretika (klortalidom) dovela je do dodatnog sniženja krvnog tlaka u usporedbi s drugim antihipertenzivom kad se primjenjivao sam.
Coadministration of Ipreziv 40 and 80 mg with a calcium channel blocker (amlodipine) or a thiazide- type diuretic (chlortalidone) resulted in additional blood pressure reductions compared with the other antihypertensive alone.
Istovremena primjena Ipreziva u dozi od 40 ili 80 mg s blokatorima kalcijevih kanala (amlodipinom) ili tiazidnom vrstom diuretika (klortalidonom) dovela je do dodatnog sniženja krvnog tlaka u usporedbi s drugim antihipertenzivom kad se primjenjivao sam.
Coadministration of IV parecoxib 40 mg with propofol (CYP2C9 substrate) or midazolam (CYP3A4 substrate) did not affect either the pharmacokinetics (metabolism and exposure) or the pharmacodynamics (EEG effects, psychomotor tests and waking from sedation) of IV propofol or IV midazolam.
Istodobna primjena i.v. parekoksiba u dozi od 40 mg s propofolom (supstratom CYP2C9) ili midazolamom (supstratom CYP3A4) nije utjecala niti na farmakokinetiku (metabolizam i izloženost) niti na farmakodinamiku (EEG učinke, psihomotorne testove i buđenje iz sedacije) i.v. propofola i i.v. midazolama.
Coadministration of Levodopa/Carbidopa/Entacapone Orion with non-selective monoamine oxidase (MAO-A and MAO-B) inhibitors (e.g. phenelzine, tranylcypromine).
Istodobna primjena Levodopa/Carbidopa/Entacapone Oriona s neselektivnim inhibitorima monoaminooksidaze (MAO-A i MAO-B) (npr. fenelzin, tranilcipromin).
Coadministration of lurasidone with digoxin (a P-gp substrate) did not increase the exposure to digoxin and only slightly increased Cmax (1.3 –fold) and therefore, it is considered that lurasidone can be coadministered with digoxin.
Istovremena primjena lurasidona s digoksinom (P-gp supstratom) nije povećavala izloženost digoksinu i tek je blago povećavala Cmax (1,3 puta) pa se zbog toga smatra da se lurasidon može davati istovremeno s digoksinom.
Coadministration of lurasidone with diltiazem (slow-release formulation), a moderate CYP3A4 inhibitor, resulted in a 2.2 and 2.4-fold increase in exposure of lurasidone and ID-14283 respectively (see section 4.2).
Istovremena primjena lurasidona s diltiazemom (formulacija sa sporim oslobađanjem), umjerenim inhibitorom CYP3A4, rezultira 2,2 puta većom izloženošću lurasidonu i 2, 4 puta ID-14283 (vidjeti dio 4.2).
Coadministration of potent enzyme inducers of CYP3A4 may decrease the bioavailibity of Ketoconazole HRA.
Istovremena primjena snažnih enzimskih induktora CYP3A4 može smanjiti bioraspoloživost Ketoconazolea HRA.
Coadministration of repeated doses of crizotinib (250 mg twice daily ) with repeated doses of rifampicin (600 mg once daily), a strong CYP3A4 inducer, resulted in 84% and 79% decreases in crizotinib steady-state AUCtau and Cmax, respectively, compared to when crizotinib was given alone.
Istodobna primjena ponovljenih doza krizotiniba (250 mg dvaput dnevno) s ponovljenim dozama rifampicina (600 mg jedanput dnevno), snažnim induktorom CYP3A, rezultirala je smanjenjem AUCtau i Cmax krizotiniba u stanju dinamičke ravnoteže za 84% odnosno za 79% u odnosu na vrijednosti zabilježene kada se krizotinib primjenjivao samostalno.
Coadministration of St John's wort (Hypericum perforatum) (see section 4.5).
Istodobna primjena gospine trave (Hypericum perforatum) (vidjeti dio 4.5).
Coadministration of Stalevo with non-selective monoamine oxidase (MAO-A and MAO-B) inhibitors (e.g. phenelzine, tranylcypromine).
Istodobna primjena Staleva s neselektivnim inhibitorima monoaminooksidaze (MAO-A i MAO-B) (npr. fenelzin, tranilcipromin).
Coadministration of voriconazole and low-dose ritonavir (100 mg BID) should be avoided unless an assessment of the benefit/risk
i niske doze ritonavira (100 mg BID) treba izbjegavati, osim kad
Coadministration of voriconazole and low-dose ritonavir (100 mg twice daily) should be avoided unless an assessment of the benefit/risk to the patient justifies the use of voriconazole (see sections 4.3 and 4.5).
Treba izbjegavati istodobnu primjenu vorikonazola i niske doze ritonavira (100 mg dvaput na dan) osim ako se procijeni da omjer koristi i rizika za bolesnika opravdava primjenu vorikonazola (vidjeti dijelove 4.3 i 4.5).
Coadministration of voriconazole and sirolimus is contraindicated (see section 4.3).
Istodobna primjena vorikonazola i sirolimusa je kontraindicirana (vidjeti dio 4.3).
Coadministration with a high-fat and high-calorie meal slows the rate of absorption, decreasing mean plasma Cmax by approximately 27%, but has minimal effect on the overall extent of absorption with an 8% decrease in mean AUC.
Istodobna primjena punomasnih i visokokaloričnih obroka kod zdravih dobrovoljaca usporava brzinu apsorpcije, smanjuje Cmax u plazmi za 25%, ali minimalno utječe na ukupni opseg apsorpcije uz 8% smanjenja AUC.
Coadministration with a selective MAO-A inhibitor and a selective MAO-B inhibitor (see section 4.5).
Istodobna primjena sa selektivnim MAO-A inhibitorom i selektivnim MAO-B inhibitorom (vidjeti dio 4.5).
Coadministration with agents that induce 3A4 activity may reduce the efficacy of Effentora.
Istovremena primjena s lijekovima koji induciraju aktivnost 3A4 može reducirati djelotvornost Effentore.
Coadministration with enzyme inducers may increase the risk of adverse events and ALT elevations (see Table 2).
Istodobna primjena s induktorima enzima može povećati rizik od nuspojava i porasta razine ALT-a (vidjeti Tablicu 2).
Coadministration with ethinylestradiol may increase the risk of ALT elevations (see sections 4.3 and 4.4).
Istodobna primjena s etiniliestradiolom može povećati rizik od porasta razine ALT- a (vidjeti dijelove 4.3 i 4.4.).
Coadministration with herbal preparations containing St John’s wort (Hypericum perforatum) due to the risk of decreased plasma concentrations and reduced clinical effects of nevirapine (see section 4.5).
Istodobna primjena s biljnim pripravcima koji sadrže gospinu travu (Hypericum perforatum) zbog rizika od smanjenja koncentracija u plazmi te smanjenih kliničkih učinaka nevirapina (vidjeti dio 4.5.).
Coadministration with herbal preparations containing St. John’s wort (Hypericum perforatum) due to the risk of decreased plasma concentrations and reduced clinical effects of nevirapine (see section 4.5).
Istodobna primjena s biljnim pripravcima koji sadrže gospinu travu (Hypericum perforatum) zbog rizika od smanjenja koncentracija u plazmi te smanjenih kliničkih učinaka nevirapina (vidjeti dio 4.5).
Coadministration with medicinal products that increase gastric pH
Istodobna primjena s lijekovima koji povisuju želučani pH
Coadministration with medicinal products that strongly induce cytochrome P450 3A4 (CYP3A4) and P-glycoprotein transporter (P-gp) and thus may lead to lower exposure and loss of efficacy of Daklinza.
Istodobna primjena s lijekovima koji snažno induciraju citokrom P450 3A4 (CYP3A4) i transporter P- glikoprotein (P-gp) mogu smanjiti izloženost lijeku Daklinza i dovesti do gubitka njegove djelotvornosti.
Coadministration with St John’s Wort (see section 4.5).
Istodobna primjena s gospinom travom (vidjeti dio 4.5).
Coadministration with St. John’s Wort (see section 4.5).
Istodobna primjena s gospinom travom (vidjeti dio 4.5).
Coadministration witha selective MAO-A inhibitor and a selective MAO-B inhibitor (see section 4.5).
Istodobna primjena sa selektivnim MAO-A inhibitorom i selektivnim MAO-B inhibitorom (vidjeti dio 4.5).